XML 34 R22.htm IDEA: XBRL DOCUMENT v3.23.2

Collaboration and License Agreement (Tables)

6 Months Ended

Jun. 30, 2023

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Schedule of Revenue From Collaboration Agreements

The following table presents revenue from collaboration agreements:

		Three Months Ended June 30,								Six Months Ended June 30,
		2023				2022				2023				2022
		(in thousands)
Roche Collaboration and License Agreement		$	4,825			$	—			$	10,137			$	—
Bristol Myers Squibb Collaboration and License Agreement			14,951				679				15,317				1,087
Ono Collaboration Agreement			10,473				—				10,473				—
Total revenue		$	30,249			$	679			$	35,927			$	1,087

Roche

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Schedule of Transaction Price Performance Obligations

Based on the relative stand-alone selling price, the allocation of the transaction price to the separate performance obligations is as follows:

Performance obligation		Transaction price
		(in thousands)
Combined licenses		$	105,327
Completion of Continuing Trials			30,585
Transfer of clinical trial materials			2,714
Total transaction price		$	138,626

Schedule of Deferred Revenue

Deferred revenue pertaining to the Roche Agreement		Completion of Continuing Trials
		(in thousands)
Balance as of December 31, 2022		$	17,957
Increase in collaboration revenue receivable			4,000
Recognition as revenue, as the result of performance obligations satisfied			(5,312	)
Balance as of March 31, 2023		$	16,645
Recognition as revenue, as the result of performance obligations satisfied			(4,825	)
Balance as of June 30, 2023		$	11,820
Classified as short-term		$	11,125
Classified as long-term			695

Bristol-Myers Squibb Company

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Schedule of Transaction Price Performance Obligations

Based on the relative stand-alone selling price, the allocation of the transaction price to the separate performance obligations was as follows:

Performance obligation		Transaction price
		(in thousands)
Research activities		$	6,405
Options to license druggable targets			31,148
Options to license undruggable targets			12,447
Total transaction price		$	50,000

Schedule of Deferred Revenue

Deferred revenue pertaining to the BMS Agreement		Research activities			Options to license druggable targets			Options to license undruggable targets			Total
		(in thousands)
Balance as of December 31, 2022		$	2,448		$	12,459		$	12,447		$	27,354
Recognition as revenue, as the result of performance obligations    satisfied			(366	)		-			-			(366	)
Balance as of March 31, 2023		$	2,082		$	12,459		$	12,447		$	26,988
Increase in collaboration revenue receivable			-			1,250			-			1,250
Recognition as revenue, as the result of performance obligations    satisfied			(1,242	)		(13,709	)		-			(14,951	)
Balance as of June 30, 2023		$	840		$	-		$	12,447		$	13,287
Classified as short-term		$	840		$	-		$	12,447		$	13,287
Classified as long-term			-			-			-			-

Ono Pharmaceutical Company Ltd

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Schedule of Deferred Revenue

Deferred revenue pertaining to the Ono Agreement		Research activities
		(in thousands)
Balance as of December 31, 2022		$	10,473
Recognition as revenue, as the result of performance obligations satisfied			-
Balance as of March 31, 2023		$	10,473
Recognition as revenue, as the result of performance obligations satisfied			(10,473	)
Balance as of June 30, 2023		$	-

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.

+ References

No definition available.

+ Details

Name:	us-gaap_DeferredRevenueByArrangementDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	dei_LegalEntityAxis=rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	dei_LegalEntityAxis=rptx_BristolMyersSquibbCompanyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	dei_LegalEntityAxis=rptx_OnoPharmaceuticalCompanyLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: